文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

γ-干扰素激活树突状细胞的效率及其与 Toll 样受体激动剂的潜在协同作用。

Efficiency of Interferon-γ in Activating Dendritic Cells and Its Potential Synergy with Toll-like Receptor Agonists.

机构信息

Department of Biological Systems Engineering, College of Agriculture and Life Sciences & College of Engineering, Virginia Tech, Blacksburg, VA 24061, USA.

出版信息

Viruses. 2023 May 19;15(5):1198. doi: 10.3390/v15051198.


DOI:10.3390/v15051198
PMID:37243284
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10224459/
Abstract

Interferon-γ (IFN-γ) is a cytokine that plays an important role in immune regulation, especially in the activation and differentiation of immune cells. Toll-like receptors (TLRs) are a family of pattern-recognition receptors that sense structural motifs related to pathogens and alert immune cells to the invasion. Both IFN-γ and TLR agonists have been used as immunoadjuvants to augment the efficacy of cancer immunotherapies and vaccines against infectious diseases or psychoactive compounds. In this study, we aimed to explore the potential of IFN-γ and TLR agonists being applied simultaneously to boost dendritic cell activation and the subsequent antigen presentation. In brief, murine dendritic cells were treated with IFN-γ and/or the TLR agonists, polyinosinic-polycytidylic acid (poly I:C), or resiquimod (R848). Next, the dendritic cells were stained for an activation marker, a cluster of differentiation 86 (CD86), and the percentage of CD86-positive cells was measured by flow cytometry. From the cytometric analysis, IFN-γ efficiently stimulated a considerable number of the dendritic cells, while the TLR agonists by themselves could merely activate a few compared to the control. The combination of IFN-γ with poly I:C or R848 triggered a higher amount of dendritic cell activation than IFN-γ alone. For instance, 10 ng/mL IFN-γ with 100 µg/mL poly I:C achieved 59.1% cell activation, which was significantly higher than the 33.4% CD86-positive cells obtained by 10 ng/mL IFN-γ. These results suggested that IFN-γ and TLR agonists could be applied as complementary systems to promote dendritic cell activation and antigen presentation. There might be a synergy between the two classes of molecules, but further investigation is warranted to ascertain the interaction of their promotive activities.

摘要

干扰素-γ(IFN-γ)是一种细胞因子,在免疫调节中发挥重要作用,尤其是在免疫细胞的激活和分化方面。Toll 样受体(TLRs)是一类模式识别受体,能够识别与病原体相关的结构基序,并向免疫细胞发出入侵警报。IFN-γ 和 TLR 激动剂都已被用作免疫佐剂,以增强癌症免疫疗法和针对传染病或精神活性化合物的疫苗的疗效。在这项研究中,我们旨在探讨同时应用 IFN-γ 和 TLR 激动剂来增强树突状细胞激活和随后的抗原呈递的潜力。简而言之,用 IFN-γ 和/或 TLR 激动剂聚肌苷酸-聚胞苷酸(poly I:C)或瑞喹莫德(R848)处理小鼠树突状细胞。然后,用流式细胞术对树突状细胞进行激活标志物(CD86)染色,并测量 CD86 阳性细胞的百分比。从细胞计量分析中可以看出,IFN-γ 有效地刺激了相当数量的树突状细胞,而 TLR 激动剂本身与对照相比只能激活少数树突状细胞。IFN-γ 与 poly I:C 或 R848 联合使用可引发比单独使用 IFN-γ 更高水平的树突状细胞激活。例如,10ng/mL IFN-γ 与 100μg/mL poly I:C 可达到 59.1%的细胞激活率,明显高于 10ng/mL IFN-γ 获得的 33.4%CD86 阳性细胞。这些结果表明,IFN-γ 和 TLR 激动剂可作为互补系统应用,以促进树突状细胞激活和抗原呈递。这两类分子之间可能存在协同作用,但需要进一步研究以确定它们的促进活性的相互作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73da/10224459/d68f98bdd293/viruses-15-01198-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73da/10224459/0eb046df62f7/viruses-15-01198-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73da/10224459/cf506c100978/viruses-15-01198-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73da/10224459/517b1592d3bd/viruses-15-01198-g003a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73da/10224459/c5505348ae1a/viruses-15-01198-g004a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73da/10224459/d68f98bdd293/viruses-15-01198-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73da/10224459/0eb046df62f7/viruses-15-01198-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73da/10224459/cf506c100978/viruses-15-01198-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73da/10224459/517b1592d3bd/viruses-15-01198-g003a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73da/10224459/c5505348ae1a/viruses-15-01198-g004a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73da/10224459/d68f98bdd293/viruses-15-01198-g005.jpg

相似文献

[1]
Efficiency of Interferon-γ in Activating Dendritic Cells and Its Potential Synergy with Toll-like Receptor Agonists.

Viruses. 2023-5-19

[2]
The influence of CD40 ligation and interferon-gamma on functional properties of human monocyte-derived dendritic cells activated with polyinosinic-polycytidylic acid.

Vojnosanit Pregl. 2011-4

[3]
Toll like receptor agonists augment HPV 11 E7-specific T cell responses by modulating monocyte-derived dendritic cells.

Arch Dermatol Res. 2009-7-4

[4]
Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-derived dendritic cells.

J Immunother Cancer. 2022-6

[5]
Activation of human CD141 and CD1c dendritic cells in vivo with combined TLR3 and TLR7/8 ligation.

Immunol Cell Biol. 2018-2-10

[6]
Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells.

Infect Immun. 2005-12

[7]
Combined CpG and poly I:C stimulation of monocytes results in unique signaling activation not observed with the individual ligands.

Cell Signal. 2013-7-19

[8]
Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice.

Cancer Immunol Immunother. 2011-2-16

[9]
TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production.

J Immunol. 2005-8-1

[10]
Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma.

J Immunol. 2005-1-15

引用本文的文献

[1]
The immunological and pharmacokinetic evaluation of Lipid-PLGA hybrid nanoparticle-based oxycodone vaccines.

Biomaterials. 2025-2

[2]
The Role of Natural Killer Cells in Oncolytic Virotherapy: Friends or Foes?

Vaccines (Basel). 2024-6-28

[3]
Global trends in tumor microenvironment-related research on tumor vaccine: a review and bibliometric analysis.

Front Immunol. 2024

[4]
Design of a Multi-Epitope Vaccine against through Immunoinformatics Approaches.

J Fungi (Basel). 2024-1-5

[5]
The Potential of Dendritic Cell Subsets in the Development of Personalized Immunotherapy for Cancer Treatment.

Curr Issues Mol Biol. 2023-10-1

本文引用的文献

[1]
PDZ Proteins SCRIB and DLG1 Regulate Myeloma Cell Surface CD86 Expression, Growth, and Survival.

Mol Cancer Res. 2022-7-6

[2]
Recent Advances in the Development of Toll-like Receptor Agonist-Based Vaccine Adjuvants for Infectious Diseases.

Pharmaceutics. 2022-2-16

[3]
Toll-like receptor 3 (TLR3) regulation mechanisms and roles in antiviral innate immune responses.

J Zhejiang Univ Sci B. 2021-8-15

[4]
A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy.

J Exp Clin Cancer Res. 2021-6-25

[5]
Adjuvant properties of IFN-γ and GM-CSF in the scFv6.C4 DNA vaccine against CEA-expressing tumors.

Gene Ther. 2023-2

[6]
Emerging concepts in the science of vaccine adjuvants.

Nat Rev Drug Discov. 2021-6

[7]
R848 Is Involved in the Antibacterial Immune Response of Golden Pompano () Through TLR7/8-MyD88-NF-κB-Signaling Pathway.

Front Immunol. 2020

[8]
TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases.

Pharmaceutics. 2021-1-22

[9]
All About the RNA: Interferon-Stimulated Genes That Interfere With Viral RNA Processes.

Front Immunol. 2020

[10]
Emerging Adjuvants for Cancer Immunotherapy.

Front Chem. 2020-7-30

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索